Challenges for the Development of Immunotherapeutics for Cancer and Role of Fresh Patient Tissue Model in IO Drug Development 2017
WebcastFaculty
OVERVIEW
Challenges for the Development of Immunotherapeutics for Cancer and Role of Fresh Patient Tissue Model in IO Drug Development is organized by Cambridge Healthtech Institute and would be held on Nov 01, 2017.
Cancer immunotherapy delivers treatment of high speci?city, low toxicity and prolonged activity in subsets of patients. With this revolutionary treatment approach, immunotherapy has had unprecedented momentum resulting in mounting experimental strategies and not enough patients for clinical trials. Understanding the immunosuppressive mechanisms in the tumor immune microenvironment is essential to predicting drug response and development of biomarkers. Utilizing novel assays, including un-propagated fresh patient platforms with intact immune microenvironment will help facilitate immuno-oncology drug development, including biomarker discovery, biomarker-driven rational drug combinations and de-risking drug development with a higher probability of clinical success.
Conference Objectives are :
• Introduce immunotherapy, current drugs in market and the importance of the tumor immune microenvironment.
• Understand the challenges associated with the development of immunotherapy drugs.
• Learn about novel options including fresh patient tissue models and their application in immunotherapy drug development.
Additional details will be posted as soon as they are available.
Cancer immunotherapy delivers treatment of high speci?city, low toxicity and prolonged activity in subsets of patients. With this revolutionary treatment approach, immunotherapy has had unprecedented momentum resulting in mounting experimental strategies and not enough patients for clinical trials. Understanding the immunosuppressive mechanisms in the tumor immune microenvironment is essential to predicting drug response and development of biomarkers. Utilizing novel assays, including un-propagated fresh patient platforms with intact immune microenvironment will help facilitate immuno-oncology drug development, including biomarker discovery, biomarker-driven rational drug combinations and de-risking drug development with a higher probability of clinical success.
Conference Objectives are :
• Introduce immunotherapy, current drugs in market and the importance of the tumor immune microenvironment.
• Understand the challenges associated with the development of immunotherapy drugs.
• Learn about novel options including fresh patient tissue models and their application in immunotherapy drug development.
Additional details will be posted as soon as they are available.
SPECIALITIES
OncologyImmunology and Microbiology
Quick Links